Baxter International Inc. Share Price

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 21:00:03 31/05/2024 BST 5-day change 1st Jan Change
34.1 USD +2.90% Intraday chart for Baxter International Inc. +0.59% -11.80%
Sales 2024 * 15.11B 1,186B Sales 2025 * 15.66B 1,230B Capitalization 17.37B 1,364B
Net income 2024 * 703M 55.18B Net income 2025 * 950M 74.57B EV / Sales 2024 * 1.8 x
Net Debt 2024 * 9.85B 773B Net Debt 2025 * 9.06B 711B EV / Sales 2025 * 1.69 x
P/E ratio 2024 *
18.5 x
P/E ratio 2025 *
15.2 x
Employees 60,000
Yield 2024 *
3.5%
Yield 2025 *
3.64%
Free-Float 74.27%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.90%
1 week+0.59%
Current month+0.03%
1 month-15.47%
3 months-16.85%
6 months-6.70%
Current year-11.80%
More quotes
1 week
33.00
Extreme 33
34.11
1 month
33.00
Extreme 33
37.43
Current year
33.00
Extreme 33
44.01
1 year
31.01
Extreme 31.01
50.21
3 years
31.01
Extreme 31.01
89.70
5 years
31.01
Extreme 31.01
95.19
10 years
31.01
Extreme 31.01
95.19
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 30/09/15
Director of Finance/CFO 54 17/10/23
Chief Tech/Sci/R&D Officer - 31/12/16
Members of the board TitleAgeSince
Director/Board Member 73 05/02/17
Director/Board Member 64 09/05/22
Director/Board Member 64 17/02/19
More insiders
Date Price Change Volume
31/05/24 34.09 +1.97% 5,923,067
30/05/24 33.43 +0.72% 3,888,886
29/05/24 33.19 -1.95% 4,258,847
28/05/24 33.85 -0.15% 3,571,396
24/05/24 33.9 -0.29% 4,982,159

Delayed Quote Nyse, May 31, 2024 at 09:00 pm

More quotes
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
34.09 USD
Average target price
45.44 USD
Spread / Average Target
+33.29%
Consensus